RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has filed a patent infringement lawsuit against Cellectis SA (ALCLS) and a number of its affiliates in the U.S. District Court for the Eastern District of North Carolina. The lawsuit seeks a ruling that Cellectis’ manufacture, use, sale, and importation of certain engineered meganucleases infringe U.S. Patent No. 8,304,222 (the “‘222 patent”), which relates to Precision BioSciences’ Directed Nuclease EditorTM genome editing technology. The lawsuit requests monetary damages as well as a permanent injunction preventing Cellectis from making, using, selling, offering for sale, or importing infringing engineered meganucleases in the United States. Precision BioSciences previously announced that it had filed suit against Cellectis for alleged infringement of U.S. Patent Nos. 8,021,867, 8,119,381, 8,119,361, 8,124,369, 8,129,134, 8,133,697, 8,143,015, 8,143,016, 8,148,098, and 8,163,514.
